Blockchain Registration Transaction Record

Tonix Pharmaceuticals Reports Q1 2025 Results and Progress Across Pipeline

Tonix Pharmaceuticals announces Q1 2025 results and progress across pipeline, highlighting advancements in fibromyalgia treatment. FDA decision for TNX-102 SL could revolutionize pain management. Important news for investors in biopharmaceutical sector.

Tonix Pharmaceuticals Reports Q1 2025 Results and Progress Across Pipeline

This news matters as it showcases Tonix Pharmaceuticals' financial performance and advancements in developing innovative therapies for pain management and public health challenges. The FDA decision for TNX-102 SL could mark a significant milestone in fibromyalgia treatment, providing new options for patients. Investors and stakeholders in the biopharmaceutical industry should take note of Tonix's promising developments.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x747ad918a4abdc7ab8a9aea393ecd2fcc81dd18cae34843af0a94d564fb4a9a2
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintmielUxhT-c1c120f20c69abbcf961829a1a00c74e